Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy
- 206 Downloads
Background Previous studies have evaluated the simplification of HIV treatment with ritonavir-boosted protease inhibitor monotherapy, demonstrating acceptable efficacy and advantages such as avoidance of the adverse effects of reverse transcriptase inhibitors. To achieve the best results, patients should be appropriately selected for this therapy. Objective The purpose of this study was to estimate the proportion of HIV patients suitable for boosted protease inhibitor monotherapy according to clinical trial criteria. Setting The study was conducted in the outpatient hospital pharmacy service of the Complejo Hospitalario de Navarra in northern Spain. Method A retrospective analysis was performed on data from 635 adults on antiretroviral therapy. The eligibility criteria were: (1) >18 years of age; (2) prior triple-drug antiretroviral regimen; (3) durability of current treatment >18 months; (4) viral load <400 copies/mL over the 18 months before evaluation and <50 copies/mL over the last 6 months; (5) CD4 count ≥250 cells/μL; (6) CD4 count nadir >100 cells/μL; (7) no previous virological failure under prior protease inhibitor-based regimen; (8) absence of co-infection with hepatitis B virus; (9) absence of HIV-related neurological disease; and (10) adherence >95 %. The average cost of the current treatment was calculated for patients who met all criteria, as well as the potential economic impact of simplification to monotherapy. Main outcome measure Number of patients meeting all criteria for simplification to monotherapy according to clinical trial standards. Results One hundred and three patients (16.5 %) met the clinical trial criteria for protease inhibitor monotherapy. One hundred and fifty patients (24 %) failed to fulfil only one of the conditions. Fifty-four percent of the patients who met all of the criteria had been treated for more than 10 years. The average saving per patient per year was €2,850–€3,400. Conclusion This treatment strategy represents a realistic, albeit minority, option. Fulfilment of the above conditions should be the basis for simplification to protease inhibitor monotherapy, though the final decision depends on clinical criteria and patient preferences assessed by the attending physician. Further studies are needed to confirm long-term safety and efficacy.
KeywordsAIDS Antiretrovirals Boosted protease inhibitors HIV infection Monotherapy
- 1.Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2 Apr 2012.
- 3.European AIDS Clinical Society (EACS). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. 2011. http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59:eacs-guidelines&catid=37:guidelines&Itemid=41. Accessed 2 Apr 2012.
- 4.Spanish AIDS Study Group (GESIDA) and the National AIDS Plan. National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus. 2012. http://www.gesida-seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2012-Documentoconsenso-TAR-adulto-verordenador.pdf. Accessed 2 Apr 2012.
- 8.Pulido F, Matarranz M, Rodriguez-Rivera V, Fiorante S, Hernando A. Boosted protease inhibitor monotherapy. What have we learnt after seven years of research? AIDS Rev. 2010;12(3):127–34. Epub 2010/09/16.Google Scholar
- 9.Pulido Ortega F, Llenas-Garcia J. Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection. Enferm Infecc Microbiol Clin. 2008;26(Suppl 16):12–20. Epub 2009/07/03.Google Scholar
- 15.Nunes EP, Santini de Oliveira M, Merçon M, Zajdenverg R, Faulhaber JC, Pilotto JH, et al. Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials. 2009;10(6):368–74.PubMedCrossRefGoogle Scholar
- 17.Pulido F, Serrano O, Rivero A. Atazanavir/ritonavir monotherapy for maintenance of virologic suppression: 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY Study. In: Gazzard B, Lundgren J, editors. Abstracts of the 12th European AIDS conference/EACS, 11–14 Nov 2009, Cologne. HIV Med. 2009;10(Suppl 2):1–246.Google Scholar
- 22.Ibarra Barrueta O, Ortega Valín L, Grupo VIH de la SEFH. Survey of the pharmaceutical care situation of the HIV patient in Spain. Farm Hosp. 2008;32(3):170–7.Google Scholar
- 28.Perez-Valero I, Arribas JR. Protease inhibitor monotherapy. Curr Opin Infect Dis. 2011;24(1):7–11. Epub 2010/12/15.Google Scholar
- 29.Arribas JR, Pulido F, Lázaro P, Méndez I. Estudio farmacoeconómico de lopinavir/ritonavir en monoterapia en el ensayo clínico OK04. PharmacoEconomics—Spanish Research Articles. 2011;8(3):85–97.Google Scholar